Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited survival gains despite advances in systemic therapy. More than 90% of PDAC tumors harbor activating RAS mutations, making RAS signaling a central therapeutic target.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited survival gains despite advances in systemic therapy. More than 90% of PDAC tumors harbor activating RAS mutations, making RAS signaling a central therapeutic target. However, effective inhibition of the broader spectrum of RAS alterations in pancreatic cancer has remained a major challenge.
Problem Statement
Most currently available targeted therapies address only selected KRAS subtypes, while the majority of RAS-mutated PDAC lacks effective precision treatment options after progression on standard chemotherapy. A therapeutic strategy capable of targeting multiple active RAS variants simultaneously could potentially overcome this limitation and expand the applicability of RAS-directed therapy in pancreatic cancer.
Summary
This phase 1–2 study demonstrates encouraging clinical activity of daraxonrasib, a multiselective RAS(ON) inhibitor, in previously treated RAS-mutated PDAC. Daraxonrasib targets active guanosine triphosphate-bound mutant and wild-type RAS, enabling broader inhibition across multiple RAS mutation subtypes rather than focusing on a single KRAS alteration. In heavily pretreated patients, the drug produced meaningful objective response rates, particularly in tumors harboring RAS G12 mutations, with durable responses and progression-free survival outcomes that compare favorably with existing second-line therapies in PDAC. Importantly, responses were also observed across broader RAS mutation groups, suggesting potential applicability beyond highly selected molecular subsets. Toxicities were common but largely manageable, with gastrointestinal adverse effects, rash and mucosal toxicity representing the dominant treatment-related events. Approximately one-third of patients experienced grade 3 or higher adverse events, indicating that tolerability remains an important consideration in further development. Overall, this study represents one of the most promising advances in broad-spectrum RAS inhibition for pancreatic cancer and supports the emergence of pan-RAS targeting as a potentially transformative therapeutic strategy in RAS-driven solid tumors.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.